| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
|---|---|---|---|---|---|---|
|
|
body size and weight | Body weight, body length, body mass index. Aging study, 6mo, 12mo, 20mo. | inbred (32) | both | 26, 52, 87 wks | 2008 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, body area, bone area. Aging study, 6mo, 12mo, 20mo. | inbred (32) | both | 26, 52, 87 wks | 2008 |
|
|
body weight | Body weight | inbred (13) | m | 7-8wks | 2011 |
|
|
bottle choice test | Sodium chloride solution taste threshold. Fluid intake. | inbred (13) | m | 7-8wks | 2011 |
|
|
intake monitoring | Water intake. Daily. | inbred (13) | m | 7-8wks | 2011 |
|
|
genotype assessment | Gpr84 allele assessment. PCR, sequencing. | inbred w/CC8 (58) | both | 6wks | 2013 |
|
|
immune cell quantification | Regulatory T cells (Treg), thymus, spleen. | inbred (33) | m | 5-6wks | 2007 |
|
|
ventilator
with methacholine |
Airway resistance. Baseline vs. methacholine-challenged (several doses). | inbred (37) | both | 9-12wks | 2010 |
|
|
plethysmography
with methacholine |
Lung, respiratory function. Baseline vs. methacholine-challenged (several doses). | inbred (29) | both | 9-12wks | 2010 |
|
|
ventilator
with methacholine |
Lung, respiratory function. Anesthetized forced oscillation. Baseline vs. methacholine-challenged (several doses). | inbred (29) | both | 9-12wks | 2010 |
|
|
metabolite quantification | Vitamin D concentration (serum). | inbred (18) | m | 11wks | 2011 |
|
|
histopathology | Lung adenoma frequency and severity at 20mo. Tumor incidence, cancer, aging. | inbred (28) | both | 87wks | 2011 |
|
|
intake monitoring
with sucrose |
Food, caloric, water intake. Baseline and with sucrose (several concentrations). 24h test. | inbred (12) | m | 13-17wks | 2006 |
|
|
open field test | Locomotor activity and exploratory behavior. 5 min test in dark. | inbred (10) | both | 8-14wks | 2000 |
|
|
fear conditioning test | Contextual fear, cued fear. | inbred (8) | both | 9-20wks | 2001 |
|
|
open field test | Locomotor activity, exploratory behavior, habituation scores. 15 min test. | inbred (14) | m | 8-12wks | 2009 |
|
|
health assessment
with Plasmodium berghei |
Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. | inbred (31) | both | 8-12wks | 2010 |
|
|
genotyping | SNP profiling, 131,000+ genomic locations, 1-19,X. | inbred (89) | 2009 | ||
|
|
complete blood count | Hematology. | inbred (10) | both | 8wks | 2013 |
|
|
ion transport assessment | Hematology red cell ion content, ion transport. | inbred (10) | both | 8wks | 2013 |
|
|
genotyping | SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. | inbred (142) | m | 2014 | |
|
|
immune cell quantification | Natural killer T cells in peripheral blood, spleen, thymus. | inbred (38) | both | 8-10wks | 2011 |
|
|
body temperature
with diazepam |
Baseline vs. 30 min after diazepam injection (several doses). | inbred (15) | both | 6-7wks | 1998 |
|
|
drug and metabolite quantification
with diazepam |
Diazepam (and metabolite) concentration in brain tissue immediately after diazepam injection and rotarod. | inbred (15) | both | 6-7wks | 1998 |
|
|
monitoring system
with diazepam |
Locomotor activity. Baseline vs. immediately after Diazepam injection (several doses). 15 min test. | inbred (15) | both | 6-7wks | 1998 |
|
|
rotarod
with diazepam |
Latency to fall from 5 rpm rotarod immediately after diazepam injection. | inbred (15) | both | 6-7wks | 1998 |
|
|
behavior observation
with haloperidol |
Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
body weight
with haloperidol |
Baseline vs. after haloperidol 60d implant. | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
drug and metabolite quantification
with haloperidol |
Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
inclined screen test
with haloperidol |
Baseline vs. during and after haloperidol 60d implant (several timepoints). | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
open field test
with haloperidol |
Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test. | inbred w/CC8 (27) | m | 9-28wks | 2012 |
|
|
body weight
with sucrose |
Effect on body weight of several days in a lever-based oral sucrose self-administering system. | HMDP (91) | m | 7-22wks | 2018 |
|
|
operant conditioning chamber
with sucrose |
Rewards behavior and learning in a lever-based oral sucrose self-administering system. Daily 8 h sessions for 3 days. | HMDP (91) | m | 7-22wks | 2018 |
|
|
body weight | Body weight | inbred (13) | both | 10wks | 2004 |
|
|
organ weights | Heart, kidney, thymus, adrena weights. | inbred (13) | both | 10wks | 2004 |
|
|
tail cuff | Blood pressure. | inbred (13) | both | 10wks | 2004 |
|
|
in vitro assay
with Bacillus anthracis lethal toxin |
Bacillus anthracis lethal toxin (anthrax) susceptibility. | inbred (50) | f | 6-8wks* | 1998 |
|
|
urinalysis | Microalbumin, creatinine, ratio. | inbred w/CC7 (34) | m | 10wks | 2012 |
|
|
immunoglobulin quantification | Immunoglobulin concentrations (serum). | inbred (6) | both | 9-12wks | 2008 |
|
|
body weight | Body weight | inbred (14) | both | 9-12wks | 2003 |
|
|
bone dimensions | Craniofacial bone dimensions. | inbred (14) | both | 9-12wks | 2003 |
|
|
body weight | Body weight | inbred (14) | both | 25wks | 2009 |
|
|
intake monitoring | Food intake, water intake at 6mo. Light phase, dark phase, total. | inbred (14) | both | 25wks | 2009 |
|
|
monitoring system | Locomotor activity. Aging study. 24h test with 12h light and 12h dark phases. | inbred (14) | both | 25wks | 2009 |
|
|
elevated zero maze | Anxiety-related behaviors. | inbred (8) | both | 8-9wks | 2001 |
|
|
electroconvulsion test
with lamotrigine |
Electroconvulsive thresholds. Lamotrigine. 2 test sites. | inbred (16) | both | 6-11wks | 2000 |
|
|
tail cuff
with sodium chloride |
Heart rate and blood pressure. Sodium chloride (1% solution for 2wks) vs. control. | inbred (11) | both | 9-12wks | 2003 |
|
|
drug and metabolite quantification
with lithium |
Lithium concentration in brain tissue and blood serum after lithium (several doses). | inbred (11) | m | 7-8wks | 2011 |
|
|
forced swim test
with lithium |
Lithium (several doses) vs. control. 6 min test. | inbred (11) | m | 7-8wks | 2011 |
|
|
behavior observation
with nicotine |
Observed measures of anxiety. Nicotine (high dose) vs. control. 20 min period. | inbred (8) | m | 8-12wks | 2011 |
|
|
drug and metabolite quantification
with nicotine |
Amount of nicotine and cotinine in blood plasma after nicotine doses. High and lower doses. | inbred (8) | m | 8-12wks | 2011 |
|
|
elevated plus maze
with nicotine |
Measures of anxiety. Nicotine (high dose) vs. control. 5 min test. | inbred (8) | m | 8-12wks | 2011 |
|
|
fear conditioning test
with nicotine |
Contextual fear, cued fear. Nicotine (high and several lower doses) vs. control. | inbred (8) | m | 8-12wks | 2011 |
|
|
behavior observation
with nicotine |
Observed measures of anxiety during nicotine withdrawal. Nicotine (several high doses) vs. control. | inbred (8) | m | 8-12wks | 2011 |
|
|
elevated plus maze
with nicotine |
Measures of anxiety during nicotine withdrawal. Nicotine (several high doses) vs. control. | inbred (8) | m | 8-12wks | 2011 |
|
|
fear conditioning test
with nicotine |
Contextual fear, cued fear during nicotine withdrawal. Nicotine (high and several lower doses) vs. control. | inbred (8) | m | 8-12wks | 2011 |
|
|
conditioned place preference test
with nicotine |
Nicotine preference and learning effect. Nicotine-treated vs. control. 2 trials (day 5, day 10). | inbred (8) | m | 8-10wks | 2014 |
|
|
genotype assessment
with Candida albicans |
C5 allele sufficiency or deficiency. | inbred (36) | f | 8-12wks | 2011 |
|
|
in vitro assay
with Candida albicans |
Susceptibility to infection with Candida albicans. | inbred (36) | f | 8-12wks | 2011 |
|
|
health assessment
with Plasmodium chabaudi |
Survival score and susceptibility, Plasmodium chabaudi. | inbred (25) | both | 8-10wks | 2012 |
|
|
microscopy
with Plasmodium chabaudi |
Percent of Plasmodium chabaudi-infected erythrocytes in blood. | inbred (25) | both | 8-10wks | 2012 |
|
|
body weight | Body weight of newborns. | inbred (8) | both | postnatal | 2011 |
|
|
organ dimensions | Kidney morphology of newborns. Planar surface area. | inbred (8) | both | postnatal | 2011 |
|
|
organ weights | Kidney weight of newborns. | inbred (8) | both | postnatal | 2011 |
|
|
renal function assay | Vesico-ureteric reflux in newborns. Kidney function. | inbred (8) | both | postnatal | 2011 |
|
|
body weight | Daily body weight gain of cross-fostered pups. | inbred (31) | f | 14-18wks | 2012 |
|
|
colony observation | Maternal nurturing study. | inbred (31) | f | 14-18wks | 2012 |
|
|
mineral quantification | concentrations of various minerals in milk | inbred (31) | f | 14-20wks | 2018 |
|
|
ECG | Heart rate and wave intervals. Conscious. | inbred (17) | both | 9-12wks | 2001 |
|
|
body weight
with isoniazid |
Body weight. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
histopathology
with isoniazid |
Liver pathology scores. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
lipid profile
with isoniazid |
Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
metabolic panel
with isoniazid |
Alanine transaminase. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
organ weights
with isoniazid |
Body, liver, kidney weights. Isoniazid-treated vs. control. | inbred (34) | f | 8-10wks | 2011 |
|
|
biomarker quantification
with DB289 |
Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
body weight
with DB289 |
DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
drug and metabolite quantification
with DB289 |
Kidney metabolite (DB75) concentration. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
metabolic panel
with DB289 |
Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
organ weights
with DB289 |
Kidney and liver weights. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
urinalysis
with DB289 |
Urine volume, creatinine. DB289-treated vs. control. | inbred (34) | f | 6-8wks | 2012 |
|
|
bronchoalveolar lavage assessment
with radiation |
Bronchoalveolar cell differential after exposure to radiation (18 Gy). | inbred (26) | both | 15-36wks | 2012 |
|
|
health assessment
with radiation |
Survival rate and health assessment after exposure to radiation. Number of days without respiratory distress (max 26 wks). | inbred (26) | both | 15-36wks | 2012 |
|
|
histopathology
with radiation |
Post exposure to radiation. | inbred (26) | both | 15-36wks | 2012 |
|
|
ophthalmoscopy | Retinal fundoscopic examination. | inbred w/CC7 (41) | both | 6-7wks | 2008 |
|
|
slit lamp | Eye morphology. Frequency rates of disorders. | inbred w/CC7 (41) | both | 6-7wks | 2008 |
|
|
histopathology | Kidney pathology at 20mo. | inbred (23) | both | 87wks | 2014 |
|
|
DXA | Bone mineral density (whole body, femur, spine). | HMDP (96) | m | 16wks | 2011 |
|
|
metabolite quantification | Liver metabolic profiling. Molecular measures of nucleotides, peptides. 16h fast. | HMDP (106) | m | 16wks | 2014 |
|
|
lipid profile | Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. 16h fast, plasma. | HMDP (99) | m | 16wks | 2010 |
|
|
NMR | Percent fat. | HMDP (99) | m | 16wks | 2010 |
|
|
tail cuff | Heart rate and blood pressure. Conscious mice. | HMDP (58) | m | 9-10wks | 2012 |
|
|
fear conditioning test | Contextual fear, cued fear. | HMDP (94) | m | 10wks | 2011 |
|
|
metabolite quantification | Liver metabolic profiling. Molecular measures of amino acids. 16h fast. | HMDP (106) | m | 16wks | 2014 |
|
|
metabolite quantification | Liver metabolic profiling. Molecular measures of carbs, cofactors, vitamins, energy, xenobiotics. 16h fast. | HMDP (106) | m | 16wks | 2014 |
|
|
metabolite quantification | Liver metabolic profiling. Molecular measures of lipids (non-lysolipids). 16h fast. | HMDP (106) | m | 16wks | 2014 |
|
|
metabolite quantification | Liver metabolic profiling. Molecular measures of lipids (lysolipids). 16h fast. | HMDP (106) | m | 16wks | 2014 |
|
|
body weight | Body weight and growth curve from age 3wks to 10 wks, weighed weekly. | inbred (24) | both | 8wks | 2000 |
|
|
MHC haplotype tissue typing | Major histocompatibility complex (MHC) H2 haplotype. | inbred (56) | both | 2000 | |
|
|
colony observation | Reproductive performance. | inbred (33) | f | various | 1991 |
|
|
colony observation | Appearance, coat color | inbred (61) | both | 2006 | |
|
|
colony observation | Reproductive performance. | inbred (35) | f | various | 2009 |
|
|
study archive | Exome genotype data. Fastq files. | inbred (6) | m | 2013 | |
|
|
body weight | Body weight | inbred (11) | both | 8, 16 wks | 2006 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content, bone area. | inbred (11) | both | 8, 16 wks | 2006 |
|
|
body weight | Body weight | inbred (11) | both | 8, 16 wks | 2006 |
|
|
organ weights | Brain, heart, kidney, liver, spleen weights. | inbred (11) | both | 8, 16 wks | 2006 |
|
|
lipid profile | Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. | inbred (11) | both | 8, 16 wks | 2006 |
|
|
metabolic panel | Clinical blood chemistry (plasma). 4h fast. | inbred (11) | both | 8, 16 wks | 2006 |
|
|
complete blood count | Hematology. | inbred (11) | both | 8, 16 wks | 2006 |
|
|
body weight | Body weight and growth curve from age 3wks to 16wks, weighed weekly. | inbred (10) | both | 3-16wks | 2014 |
|
|
body weight | Body weight | inbred (11) | both | 8, 16 wks | 2006 |
|
|
immune cell quantification | White blood cell and immune cell differentials. | inbred (11) | both | 8, 16 wks | 2006 |
|
|
vestibular stimulus test | Vestibular function using evoked potentials. | inbred (16) | both | 49-63wks | 2003 |
|
|
complete blood count | Hematology. | inbred (16) | both | 12-16wks | 2002 |
|
|
urinalysis | Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. | inbred (30) | both | 52, 78, 104 wks | 2008 |
|
|
histopathology | Kidney pathology. Aging study, 6mo, 12mo, 20mo. | inbred (29) | m | 52, 78, 104 wks | 2013 |
|
|
open field test | Distance traveled, after first 10 min and after 55 min. | other (58) | both | 7-26wks | 2019 |
|
|
body weight | Body weight | inbred w/CC8 (62) | both | 8-14wks | 2021 |
|
|
open field test | Locomotor activity and grooming behavior. | inbred w/CC8 (62) | both | 8-14wks | 2021 |
|
|
body size and weight | Body length measurements. | inbred w/CC8 (62) | both | 10-20 wks | 2021 |
|
|
gait analysis | Angular velocity, Stride speed, Step length, Step width, and other gait metrics. | inbred w/CC8 (62) | both | 10-20 wks | 2021 |
|
|
open field test | Distance traveled. | inbred w/CC8 (62) | both | 10-20 wks | 2021 |
|
|
body weight | Body weight | inbred (41) | both | 8-9wks | 2010 |
|
|
running wheel monitoring | Distance, duration, speed. | inbred (41) | both | 8-9wks | 2010 |
|
|
histopathology | Cerebral infarct volume, stroke susceptibility. Surgical occlusion of distal medial cerebral artery (MCA) to induce ischemia. | inbred (16) | both | 11-13wks | 2009 |
|
|
body weight | Body weight | inbred (34) | both | 8wks | 2012 |
|
|
treadmill endurance test | Duration, distance, work. | inbred (34) | both | 8wks | 2012 |
|
|
body weight
with atenolol, isoproterenol |
Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
ECG
with atenolol, isoproterenol |
Heart rate and wave amplitudes and intervals. Unconscious. Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
organ weights
with atenolol, isoproterenol |
Heart, atria, ventricle weights. Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
tail cuff
with atenolol, isoproterenol |
Heart rate and blood pressure. Conscious mice. Isoproterenol or atenolol vs. control. | inbred (23) | m | 10-12wks | 2009 |
|
|
behavior observation
with ethanol |
Ethanol withdrawal severity and handling-induced convulsions. | inbred (15) | m | 8-11wks | 2005 |
|
|
body weight
with ethanol |
Body weight | inbred (15) | m | 8-11wks | 2005 |
|
|
apoptosis assessment | Aging study, 6mo, 12mo, 20mo. | inbred (30) | both | 26, 52, 87 wks | 2008 |
|
|
chromosome instability assessment | Chromosome instability. Aging study, 6mo, 12mo, 20mo. | inbred (30) | both | 26, 52, 87 wks | 2008 |
|
|
bottle choice test | Sucrose vs. water. | inbred (15) | m | 5-7wks | 2010 |
|
|
go/no-go task | Pre-cue, go cue. no-go cue. Discrimination index. | inbred (15) | m | 5-7wks | 2010 |
|
|
monitoring system | Locomotor activity. | inbred (15) | m | 5-7wks | 2010 |
|
|
nociception assay | Battery of tests for mechanical, chemical, thermal nociception. | inbred (12) | m | 6-18wks | 2002 |
|
|
monitoring system | Locomotor activity. Light and dark phases. | inbred (12) | m | 6-10wks | 2000 |
|
|
protein activity assessment | Acetylcholinesterase activity of cerebellum and dorsal and ventral hippocampus | inbred (20) | m | 8-12wks | 2021 |
|
|
fear conditioning test
with nicotine |
Percent freezing for training and testing in both contextual and cued fear conditioning. | inbred (21) | m | 8-12wks | 2021 |
|
|
body weight
with high-fat diet |
High-fat diet for 8wks. | inbred w/CC7 (43) | both | 5, 21 wks | 2003 |
|
|
DXA
with high-fat diet |
Body mass, fat mass, lean mass, bone mineral density and content after 8wks on high-fat diet. | inbred w/CC7 (43) | both | 5, 21 wks | 2003 |
|
|
hormone quantification
with high-fat diet |
Insulin and leptin after 18wks on high-fat diet. Multiple readings per animal were averaged. | inbred w/CC7 (43) | both | 5, 21 wks | 2003 |
|
|
metabolic panel
with high-fat diet |
Glucose (plasma). Baseline vs. high-fat diet (17wks). 4h fast. | inbred w/CC7 (43) | both | 5, 21 wks | 2003 |
|
|
body weight
with high-fat diet |
Baseline vs. high-fat diet for 8wks. | inbred (44) | both | 15-19wks | 2000 |
|
|
histopathology
with high-fat diet |
Gallstone, gallbladder, and atherosclerosis lesion histopathology after 8wks on high-fat diet. | inbred (44) | both | 15-19wks | 2000 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. | inbred (44) | both | 15-19wks | 2000 |
|
|
metabolic panel
with high-fat diet |
Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. | inbred (44) | both | 15-19wks | 2000 |
|
|
organ dimensions
with high-fat diet |
Gallbladder volume after 8wks on high-fat diet. | inbred (44) | both | 15-19wks | 2000 |
|
|
organ weights
with high-fat diet |
Liver weight after 8wks on high-fat diet. | inbred (44) | both | 15-19wks | 2000 |
|
|
histopathology
with high-fat diet |
Aortic lesion size histopathology. Baseline vs. high-fat diet (17wks). | inbred w/CC7 (43) | both | 7-9wks, 24-27wks | 2002 |
|
|
lipid profile
with high-fat diet |
Cholesterol, HDL, non-HDL, triglycerides. Baseline vs. high-fat diet (17wks). 4h fast, plasma. | inbred w/CC7 (43) | both | 7-9wks, 24-27wks | 2002 |
|
|
lipid profile | Cholesterol, HDL, non-HDL, triglycerides. 4h fast, plasma. | inbred w/CC7 (43) | both | 10wks | 2002 |
|
|
coagulation test | Fibrinogen. | inbred w/CC7 (43) | both | 10wks | 2001 |
|
|
complete blood count | Hematology. | inbred w/CC7 (43) | both | 10wks | 2001 |
|
|
complete blood count | Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (30) | both | 26, 52, 78, 104 wks | 2007 |
|
|
complete blood count | Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2007 |
|
|
immune cell quantification | Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2007 |
|
|
body weight | Body weight | inbred (32) | m | 7-9wks | 2007 |
|
|
hormone quantification | Corticosterone (serum). | inbred (32) | m | 7-9wks | 2007 |
|
|
open field test | Locomotor and anxiety-related behavior. 10 min test. | inbred (32) | m | 7-9wks | 2007 |
|
|
tail suspension test | Immobility percentage. | inbred (32) | m | 7-9wks | 2007 |
|
|
histopathology | Cell proliferation in the rostral migratory stream. BrdU+ cells. | inbred (9) | both | 13-78wks | 2013 |
|
|
body size and weight | Body weight, body length, body mass index. | inbred (28) | m | 8, 12 wks | 2009 |
|
|
fat pad weights | Epididymal, retroperitoneal. | inbred (28) | m | 8, 12 wks | 2009 |
|
|
organ weights | Heart, kidney weights. | inbred (28) | m | 8, 12 wks | 2009 |
|
|
genotyping | SNP profiling, 80,000,000+ genomic locations. SNPs and indels. 1-19,X. | inbred (37) | both | 2017 | |
|
|
health assessment
with pilocarpine |
Study of pilocarpine effect on epilepticus seizures. | inbred (11) | m | 8-10wks | 2012 |
|
|
body weight
with influenza A (H1N1) virus |
Influenza A (H1N1) virus vs. baseline. Several timepoints. | inbred (9) | both | 10-12wks | 2009 |
|
|
health assessment
with influenza A (H1N1) virus |
Strain susceptibility score, influenza A (H1N1) virus. | inbred (9) | both | 10-12wks | 2009 |
|
|
body weight | Body weight | inbred (16) | both | 7-9wks | 2001 |
|
|
intake monitoring | Food, caloric, and water intake. Daily. | inbred (16) | both | 7-9wks | 2001 |
|
|
monitoring system | Locomotor activity and energy metabolism. 24h test. | inbred (16) | both | 7-9wks | 2001 |
|
|
gait analysis | Aging study, 6mo, 18mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2008 |
|
|
grip strength | Peak tension. 3 trials. Aging study, 6mo, 12mo, 18mo, 24mo. | inbred (32) | both | 26, 52, 78, 104 wks | 2008 |
|
|
monitoring system | Circadian and sleep-related behavior. | inbred w/CC7 (38) | both | 10wks | 2015 |
|
|
tail cuff | Heart rate and blood pressure. Conscious mice. | inbred (25) | m | 10wks | 2007 |
|
|
tail cuff | Heart rate and blood pressure. Conscious mice. | inbred (14) | both | 9wks | 2004 |
|
|
body weight
with cocaine |
Body weight | inbred (45) | m | 8-11wks | 2015 |
|
|
open field test
with cocaine |
Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. | inbred (45) | m | 8-11wks | 2015 |
|
|
forced swim test
with ovariectomy |
Mice with ovariectomy surgery vs. controls (sham surgery), 6 min test. | inbred (37) | f | 8-10wks | 2016 |
|
|
open field test
with ovariectomy |
Locomotor activity and exploratory behavior. Mice with ovariectomy surgery vs. controls (sham surgery), 10 min test. | inbred (37) | f | 8-10wks | 2016 |
|
|
biomarker quantification
with acetaminophen |
Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
histopathology
with acetaminophen |
Liver histopathology, necrosis after acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
metabolic panel
with acetaminophen |
Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
metabolite quantification
with acetaminophen |
Liver protein homeostasis. Acetaminophen vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
organ weights
with acetaminophen |
Liver weight after acetaminophen (several doses) vs. control. 18h fast. | inbred w/CC7 (37) | m | 8-17wks | 2005 |
|
|
body weight | Body weight during testing. | inbred (28) | m | 9wks | 2001 |
|
|
bottle choice test | Various salt solutions (several concentrations) vs. water. | inbred (28) | m | 9wks | 2001 |
|
|
body weight | Body weight | inbred (28) | m | 4-12wks | 2001 |
|
|
intake monitoring | Food intake, water intake. Daily. | inbred (28) | m | 4-12wks | 2001 |
|
|
body weight | Body weight | inbred w/CC7 (40) | both | 9-15wks | 2002 |
|
|
bottle choice test | Various salt solutions (several concentrations) vs. water. | inbred w/CC7 (40) | both | 9-15wks | 2002 |
|
|
DXA | Body mass, fat mass, lean mass, bone mineral density and content. | inbred w/CC7 (40) | both | 9-15wks | 2002 |
|
|
metabolic panel | Ionized and total blood calcium, blood pH. | inbred w/CC7 (40) | both | 9-15wks | 2002 |
|
|
monitoring system | Bleeding time to collect approx 30 µL. | inbred w/CC7 (40) | both | 9-15wks | 2002 |
|
|
elevated plus maze | Exploratory and anxiety-related behaviors. 5 min test. | inbred (16) | m | 6-8wks | 1993 |
|
|
hormone quantification | Corticosterone levels (plasma). Baseline vs. after stress (30 min in restraining cage). | inbred (16) | m | 6-8wks | 1993 |
|
|
monitoring system | Novelty-induced fear test. Eating inhibition due to novelty of environment. 10 min test. | inbred (16) | m | 6-8wks | 1993 |
|
|
open field test | Locomotor activity under dim lights vs. bright lights. 5 min test. | inbred (16) | m | 6-8wks | 1993 |
|
|
genotyping | SNP profiling, 132,000+ genomic locations, 1-19,X | HMDP (248) | both | 2018 | |
|
|
body weight | Body weight | inbred (21) | both | 6-8wks | 2009 |
|
|
bone dimensions | Craniofacial bone dimensions. | inbred (21) | both | 6-8wks | 2009 |
|
|
acoustic startle test | Acoustic startle response, prepulse inhibition. | inbred w/CC7 (40) | both | 5-6wks | 2002 |
|
|
body weight | Body weight | inbred w/CC7 (40) | both | 5-6wks | 2002 |
|
|
elevated plus maze | Locomotor activity. | inbred (38) | both | 12-14wks | 2010 |
|
|
light-dark box | Light-dark test. Anxiety-related behavior. | inbred (38) | both | 12-14wks | 2010 |
|
|
open field test | Locomotor activity. | inbred (38) | both | 12-14wks | 2010 |
|
|
drug and metabolite quantification
with fluoxetine |
Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. | inbred (30) | m | 9-11wks | 2011 |
|
|
open field test
with fluoxetine |
Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. | inbred (30) | m | 9-11wks | 2011 |
|
|
tail suspension test
with fluoxetine |
Immobility. Fluoxetine-treated vs. control. 5 min test. | inbred (30) | m | 9-11wks | 2011 |
|
|
biomarker quantification
with fluoxetine |
Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. | inbred (30) | m | 10-11wks | 2011 |
|
|
immune cell quantification
with BEZ235, doxorubicin, idarubicin, selumetinib |
In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data. | inbred w/CC7 (36) | m | 10wks | 2015 |
|
|
ECG | Heart rate and wave intervals. Conscious. Aging study, 6mo, 12mo, 20mo. | inbred (29) | both | 26, 52, 87 wks | 2008 |
|
|
gait analysis | Aging study, 6mo, 12mo, 18mo. | inbred (31) | both | 26, 52, 78 wks | 2010 |
|
|
body weight | Aging study, 6mo, 12mo, and 18mo. | inbred (33) | both | 26, 52, 78 wks | 2007 |
|
|
hormone quantification | Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. | inbred (33) | both | 26, 52, 78 wks | 2007 |
|
|
colony observation | Life span study. Survival curves. Aging study. | inbred (31) | both | max lifespan | 2007 |
|
|
lipid profile | Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. | inbred (32) | both | 26, 52, 78 wks | 2008 |
|
|
metabolic panel | Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. | inbred (32) | both | 26, 52, 78 wks | 2008 |
|
|
colony observation | Observed age at vaginal opening (patency). Aging study. | inbred (33) | f | 2-9wks | 2009 |
|
|
tympanometry | Middle ear function. | inbred (61) | both | 15-51d | 2008 |
|
|
body weight | inbred (30) | both | 7-15 wks | 2020 | |
|
|
intake monitoring | Food and water intake; 2-day test, second day data analyzed during 12:12h light and dark periods. | inbred (30) | both | 7-15 wks | 2020 |
|
|
monitoring system | Voluntary activity and energy expenditure. 2-day test, second day data analyzed during 12:12h light and dark periods. | inbred (30) | both | 7-15 wks | 2020 |